Soleno Therapeutics Inc (SLNO) Return on Investment ROI from the first quarter of 2026 to first quarter of 2025 and for the year 2026, average high and low, overall ranking from Mar 31 2026 to Mar 31 2025 - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Soleno Therapeutics Inc  (NASDAQ: SLNO)


Soleno Therapeutics Inc's ROI from its first quarter of 2026 to the first quarter of 2025 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Soleno Therapeutics Inc's ROI in the first quarter of 2026?
Soleno Therapeutics Inc achieved a return on average invested assets (ROI) of 19.9 % in its first quarter of 2026, this is above SLNO's average return on investment of -77.24%.
Soleno Therapeutics Inc invested over the 12 months ending in its first quarter of 2026 $483 million

Despite the deterioration in its net income, company has improved ROI compared to the fourth quarter of 2025.

Within the Healthcare sector 58 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Mar 31 2026 quarter, so far to 341, from total ROI ranking in the fourth quarter of 2025 at 1109.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Mar 31 2026)
I. Quarter		 (Dec 31 2025)
IV. Quarter		 (Sep 30 2025)
III. Quarter		 (Jun 30 2025)
II. Quarter		 (Mar 31 2025)
I. Quarter
Y / Y Investment Change TTM 62.07 % 61.14 % 65.61 % 84.64 % 212.47 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 550 502 567 311 302
Return On Investment (TTM) 19.9 % 4.97 % -21.02 % -59.98 % -66.56 %
SLNO's Overall Ranking # 341 # 1109 # 3097 # 3102 # 3546
Seq. Investment Change TTM 14.74 % 12.75 % 23.59 % 1.38 % 14.07 %
Seq. Net Income Change TTM 359.74 % - - - -
Net Income (TTM) in Millions 96 21 -78 -181 -198

SLNO Company Profile >> Back to SLNO Roi Comparisons >> See Annual SLNO Return On Investment



Return On Investment SLNO's Ranking
Within: No.
Industry # 12
Sector # 59
Overall # 341

Return On Investment Statistics
High Average Low
19.42 %
-77.24 %
-307.33 %
(Mar 31 2026)   (Jun 30 2016)







Financial Statements
Soleno Therapeutics Inc's I. Quarter Investments $ 550 Millions SLNO's Balance sheet
Soleno Therapeutics Inc's I. Quarter Income $ 31 Millions Quarterly SLNO's Income Statement
SLNO's Income by Division See SLNO's Income by Division


SLNO Annual Return On Investment (Dec 31 2025)
2025		 (Dec 31 2024)
2024		 (Dec 31 2023)
2023		 (Dec 31 2022)
2022		 (Dec 31 2021)
2021
Total Investments in Millions 502 312 169 10 28
Y / Y Investment Growth 60.93 % 84.55 % 1534.81 % -62.43 % -51.13 %
Net Income in Millions 20 -176 -39 -24 -31
Y / Y Net Income Growth - - - - -
Annual Return On Investment 4.07 % -56.32 % -23.04 % -232.55 % -112.21 %


Annual Roi Comment
In the fiscal year 2025 ROI improved to 4.07 % compared to the prior year, due to net income growth.

Definition and Formula of Return on Investment

Other ROI Ratios
Medical Equipment & Supplies Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
SLNO's Roi Ratio versus Medical Equipment & Supplies Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for SLNO's Competitors
Subscribers only: Roi for Soleno Therapeutics Inc's Suppliers
Subscribers only: Return On Investment for SLNO's Customers

Other Ratios
SLNO's Roa SLNO's Inventory Turnover Ratio SLNO's Growth Rates SLNO's Dividend Statistics
SLNO's Profitability Ratios SLNO's Asset Turnover Ratio SLNO's Dividend Growth
SLNO's Roe SLNO's Valuation Ratios SLNO's Financial Strength Ratios SLNO's Dividend Payout Ratio



Companies with similar Return On Investment at Mar 31 2026, within Healthcare Sector ROI
Oramed Pharmaceuticals Inc  54.33 %
Aurinia Pharmaceuticals Inc   54.02 %
Vaxart Inc   51.45 %
Escalon Medical Corp   51.07 %
Tg Therapeutics Inc   50.62 %
Zevra Therapeutics Inc   50.45 %
Idexx Laboratories Inc  50.05 %
Theravance Biopharma inc   43.85 %
Elite Pharmaceuticals Inc   43.22 %
Dariohealth Corp   40.59 %
Innoviva Inc   36.71 %
Indivior Pharmaceuticals Inc   36.55 %
Eli Lilly And Company  36.13 %
Abeona Therapeutics Inc   35.03 %
Lifemd Inc   34.80 %
Acadia Pharmaceuticals Inc   34.03 %
Mettler toledo International Inc   33.62 %
Adma Biologics Inc   30.38 %
Medpace Holdings Inc   30.34 %
Spero Therapeutics Inc   29.59 %
Rafael Holdings Inc  28.08 %
Incyte Corporation  27.50 %
Carlisle Companies Incorporated  24.39 %
Iradimed Corporation  23.59 %
Catalyst Pharmaceuticals Inc   23.58 %
Engene Therapeutics Inc   22.76 %
Protalix Biotherapeutics inc   22.70 %
Electromed Inc   22.36 %
Dexcom Inc   22.17 %
Illumina Inc   22.01 %

Date modified: 2026-09-12T06:14:45+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.